OncLive Nursing FDA Updates From April 2011
3D mammogram system approved, NCCN 2011 Avastin breast cancer guidelines, and the approval of generic docetaxel.
ASCO Updates Guidelines on Bone-Modifying Drugs in Breast Cancer
ASCO releases new recommendations amid growing therapeutic options and fresh concerns about serious skeletal-related events.
New Study Findings Change the Standard of Care for Women With Breast Cancer
Contrary to the traditionally slow pace of research adoption, the American College of Surgeons Oncology Group's Z0011 trial has seemingly changed practice overnight
Advocacy Spotlight: MyLifeLine.org
MyLifeLine.org Cancer Foundation believes a strong support community is critical for cancer patients.
The Meaning of Breast Cancer Risk and Surveillance Behaviors Among High-Risk African-American Women
A breast cancer diagnosis is a highly distressing, life-changing experience
Lung Cancer Stigma, Smoking Status, Depression and Quality of Life
Negative attitudes toward smokers extend to patients with lung cancer, regardless of whether or not they have ever actually smoked
Nurse's Insight: An Interview With JTCC Advanced Practice Nurse Laura Metcalfe
As part of the Intellisphere Oncology Specialty Group's new partnership with the John Theurer Cancer Center (JTCC), our online and print coverage will provide special insight from JTCC's oncology healthcare professionals
A-List Advocacy: A Discussion of Celebrity Patients
OncLive Nursing discusses highprofile patients with Barron H. Lerner, MD, PhD, author of When Illness Goes Public: Celebrity Patients and How We Look at Medicine
Myths and Facts About Kidney Cancer
March was National Kidney Month, so here is an opportunity to test your knowledge about kidney cancer.
Lights, Camera, Advocacy! Celebrities Stand Up To Cancer
Celebrity advocacy takes the form of both individual crusades and collaborative efforts, such as Stand Up To Cancer (SU2C)
Sotigalimab/Pembrolizumab Combo Continues to Show Clinical Activity in Frontline Melanoma
Dr. Halmos on Trastuzumab Deruxtecan in NSCLC
Dr. Kris on Immunotherapy in NSCLC Without Driver Mutations
Checkpoint Inhibitor Challenges Warrant Consideration for a Targeted Approach in NSCLC
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.